Education
About Us
Working with TipRanks
Follow Us
Prime Medicine, Inc. (PRME)
NASDAQ:PRME
PRME Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.37 - $8.27
Previous CloseN/A
Volume144.88K
Average Volume (3M)1.38M
Market Cap
$211.17M
Enterprise Value$196.67M
Total Cash (Recent Filing)$187.62M
Total Debt (Recent Filing)$28.75M
Price to Earnings (P/E)―
Beta3.04
Next Earnings
May 09, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding131,160,840
10 Day Avg. Volume1,334,410
30 Day Avg. Volume1,377,927
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)85.74
Price to Cash Flow (P/CF)3.90
P/FCF Ratio3.90
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit65.93
Enterprise Value/Ebitda-1.00
Forecast
1Y Price Target
$11.80Price Target Upside736.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe addition of the AATD program expands PRME’s total addressable market and adds meaningful catalysts.
Preclinical EfficacyMouse model showed 40µM-65µM of healthy AAT levels in the serum with Prime's drug, which is ahead of peers.
Technological DifferentiationThe characteristics of prime editing, such as high specificity and versatility, are highly differentiated compared with other gene editing approaches and can potentially offer superior applicability.
Bears Say
Clinical Efficacy ConcernsIn the clinic, serum AAT levels are meaningfully lower than what was observed in mice.
Regulatory And Commercial RisksRisks include clinical, regulatory, commercial, competition, and dilution.
---
Ownership Overview
19.17% Insiders
7.25% Mutual Funds
31.39% Other Institutional Investors
33.38% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRME FAQ
What was Prime Medicine, Inc.’s price range in the past 12 months?
Prime Medicine, Inc. lowest stock price was $1.37 and its highest was $8.27 in the past 12 months.
What is Prime Medicine, Inc.’s market cap?
Prime Medicine, Inc.’s market cap is $211.17M.
When is Prime Medicine, Inc.’s upcoming earnings report date?
Prime Medicine, Inc.’s upcoming earnings report date is May 09, 2025 which is in 32 days.
How were Prime Medicine, Inc.’s earnings last quarter?
Prime Medicine, Inc. released its earnings results on Feb 28, 2025. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.351 by $0.041.
Is Prime Medicine, Inc. overvalued?
According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued.
Does Prime Medicine, Inc. pay dividends?
Prime Medicine, Inc. does not currently pay dividends.
What is Prime Medicine, Inc.’s EPS estimate?
Prime Medicine, Inc.’s EPS estimate is -0.31.
How many shares outstanding does Prime Medicine, Inc. have?
Prime Medicine, Inc. has 131,160,840 shares outstanding.
What happened to Prime Medicine, Inc.’s price movement after its last earnings report?
Prime Medicine, Inc. reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.351. Following the earnings report the stock price went up 4.132%.
Which hedge fund is a major shareholder of Prime Medicine, Inc.?
Currently, no hedge funds are holding shares in PRME
---
Prime Medicine, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.80 (736.88% Upside)
$11.80 (736.88% Upside)
Blogger Sentiment
Bullish
PRME Sentiment 83%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.64%
12-Months-Change
Fundamentals
Return on Equity
-136.88%
Trailing 12-Months
Asset Growth
54.67%
Trailing 12-Months
Company Description
Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
---
PRME Stock 12 Month Forecast
Average Price Target
$11.80
▲(736.88% Upside)
Technical Analysis
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Verve Therapeutics
―
Best Analysts Covering PRME
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-56.99%
reiterated a buy rating 20 days ago
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -56.99% per trade.
---